MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Polymorphisms in Prosaposin gene are associated with familial and early-onset Parkinson’s disease: A case-control association study and meta-analysis

    YT. Chu, MC. Kuo, YA. Su, RM. Wu (Taipei, Taiwan)

    Objective: To investigate the role of the PSAP gene in PD patients in Taiwan, including familial PD and early-onset Parkinson’s disease. Background: Mutations in the…
  • 2022 International Congress

    Altered visual network dynamics associated with freezing of gait in Parkinson’s disease

    D. Su, L. Ji, Y. Cui, J. Zhou, T. Wu, J. Stoessl, Y. Liu, T. Feng (Beijing, China)

    Objective: We aimed to characterize the dynamic functional connectivity (DFC) in people with FOG based on high temporal-resolution functional MRI (fMRI). Background: Freezing of gait…
  • 2022 International Congress

    Exploring Young people’s role in providing relief to grandparents affected with Alzheimer

    M. Busgopaul (Port Louis, Mauritius)

    Objective: In some families, children never know that their parents or grandparents are affected by the Parkinson’s Disease (PD). Whatever be the way that Movement…
  • 2022 International Congress

    A secretory vesicle failure in Parkinson’s disease occurs in human platelets

    P. Montenegro, M. Pueyo, JN. Lorenzo, R. González-Brito, A. Méndez, R. Borges (La Laguna, Spain)

    Objective: Since platelets use similar, if not the same, mechanisms to accumulate serotonin (5-HT) as dopaminergic neurons to store DA in their VS; we wonder…
  • 2022 International Congress

    Safety of opicapone after 5 years of post-marketing experience worldwide

    L. Guedes, J. Graça, M. Sampaio, M. Vieira, F. Rocha, H. Gama (Coronado, Portugal)

    Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…
  • 2022 International Congress

    Alprazolam reduces freezing of gait and improves freezing-related gait measures

    A. Al Jaja, T. Sue, K. Seergobin, J. Grahn, P. Macdonald (London, Canada)

    Objective: We investigated the effect of acutely reducing anxiety with the benzodiazepine, Alprazolam, on freezing of gait (FOG) in patients with Parkinson’s disease (PD). Background:…
  • 2022 International Congress

    EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL

    G. Mirabella, C. Mancini, O. Olivola, A. Rizzardi, V. Di Caprio, E. Ferrari, N. Modugno, A. Pilotto, A. Padovani (Brescia, Italy)

    Objective: In this study, we aim to address the effects of dopaminergic treatment (DT) on the two domains of motor inhibition [1], i.e., reactive (the…
  • 2022 International Congress

    Newly identified cases of parkinsonism and prodromal PD in a remote LRRK2 G2019S cohort

    J. Soto, S. Jensen-Roberts, T. Myers, M. Pawlik, E. Hartman, S. Lettenberger, A. Kaplan, R. Toor, R. Wilson, P. Auinger, E. Dorsey, B. Valdovinos, K. Amodeo, S. Sharma, R. Holloway, C. Tanner, R. Alcalay, R. Schneider (Rochester, USA)

    Objective: To evaluate new cases of prodromal PD and concern for parkinsonism in a cohort of LRRK2 G2019S carriers. Background: LRRK2 G2019S is a common…
  • 2022 International Congress

    Cortical oscillatory feature-based classification of Parkinson’s disease with freezing gait

    A. Singh, S. Roy, KC. Santosh (Vermillion, USA)

    Objective: The objective of this study was to determine the resting-state cortical oscillations and the machine learning model that best classifies Parkinson’s disease (PD) patients…
  • 2022 International Congress

    Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…
  • « Previous Page
  • 1
  • …
  • 516
  • 517
  • 518
  • 519
  • 520
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley